Colorectal cancer is the third most common cancer worldwide, and incidence is rising in
younger individuals. Anti-EGFR antibodies, including cetuximab and panitumumab, have …

Colorectal cancer (CRC) is one of the most common malignancies, accounting for
approximately 10% of global cancer incidence and mortality. Approximately 20% of patients …

Colorectal cancers are among the most commonly found cancers over the world. In spite of
the recent advancements in diagnosis and prognosis, the management of this metastatic …

Background Positive margins following head and neck squamous cell carcinoma (HNSCC)
surgery lead to significant morbidity and mortality. Existing Intraoperative Margin …

Background: Bevacizumab-awwb (MVASI®) was the first US Food and Drug Administration-
approved biosimilar to Avastin®(reference product [RP]) for the treatment of several different …

Background/Aim: Colorectal cancer (CRC) with reduced expression of the homeobox
transcription factor CDX2, a master gene essential for the development and maintenance of …

Colorectal cancer results in the deaths of hundreds of thousands of patients worldwide each
year, with incidence expected to rise over the next two decades. In the metastatic setting …

Simple Summary Targeted therapy targeting the EGFr and vascular endothelial growth
factor (VEGF) is often combined with chemotherapy in palliative treatment of metastatic …

Metastatic colorectal cancer continues to be a major health burden despite advances in
detection and therapy. Molecular characterization of circulating tumour cells (CTCs), main …

Biomarker is defined as indicator of normal or pathogenic biological process or response to
an intervention or exposure. There are several categories of biomarkers but predictive …